Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
- 06 July 2022 - 1 mins read
This article or press release has no online content. Please download the associated documents for more information.
Attachment
17 April 2024
4 mins read
Ipsen publishes its 2023 Universal Registration Document
08 April 2024
1 mins read
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
02 April 2024
7 mins read
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
07 March 2024
1 mins read
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
15 February 2024
1 mins read
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
13 February 2024
14 mins read
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
08 February 2024
8 mins read
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
06 February 2024
1 mins read
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
22 January 2024
10 mins read
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
08 January 2024
1 mins read